Pipeline

Improving Patient Outcomes

At SOLVD Health, we’re focused on discovering and developing novel technologies that identify an individual’s risk of developing a disease. Through the discovery and conversion of biological signals into predictive, contextual health insights, we are empowering patients and their healthcare providers with objective, actionable information to prevent disease. We’re tackling these healthcare challenges:

Designed for Change. Designed for Health.

Opioid Use Disorder

Opioid use disorder (OUD), a problematic pattern of opioid use that causes significant impairment or distress, is a treatable, chronic disease that can affect anyone — regardless of race, gender, income level, or social class. It exacts a $1.5 trillion (last measured by the Joint Economic Committee in 2020) annual toll in the United States. We want to address this crisis head-on.

No single factor can predict if a person will develop OUD following taking prescription oral opioids for acute pain. However, research has indicated that there may be genetic factors that contribute to a person’s risk for developing OUD. That’s why we developed AvertD™— a physician-ordered genetic test that analyzes 15 genetic markers to identify if a patient may have an elevated genetic risk for OUD.

We believe that AvertD will empower patients and providers to have an informed open dialogue about the benefits and risks of opioid therapy, and whether alternative pain treatments may be more appropriate.

Colon Cancer

Colon cancer is one of the most preventable forms of cancer — yet it’s the second leading cause of cancer deaths. We’re out to change that.

Through our partnership with Metabiomics, we’ve developed technology that detects biological signals associated with pre-cancerous polyps and colon cancer. Our noninvasive test analyzes an individual’s microbiome — the billions of bacteria and other microbes that live in the gut — to reveal subtle early signs of lesions that could become cancerous. We believe that through early detection and removal of these lesions, we may be able to prevent cancer before it starts. This test received FDA Breakthrough Device designation in August 2019.

Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is a hormonal disorder that affects an estimated 5 to 6 million women of childbearing age — but many don’t know they have it. It’s time for that to change.

Because women with PCOS are at higher risk of infertility and metabolic syndrome, which leads to increased risk for heart disease, diabetes, and stroke, we’re developing new technology to help improve early detection and diagnosis of PCOS. Providing early, accurate insights about PCOS to providers and patients can help support early intervention and may help prevent other chronic conditions from developing.

Partner with Us

If you are a researcher and interested in working with us, we’d love to talk.